Zimmer Biomet Holdings (Zimmer Biomet Holdings) Change In Working Capital : $-396 Mil (TTM As of Dec. 2023)

View and export this data going back to 2001. Start your Free Trial

What is Zimmer Biomet Holdings Change In Working Capital?

Zimmer Biomet Holdings's change in working capital for the quarter that ended in Dec. 2023 was $-1 Mil.

Zimmer Biomet Holdings's change in working capital for the fiscal year that ended in Dec. 2023 was $-396 Mil.

It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement. Not by calculating the number changes in each periods' working capital (Total Current Assets minus Total Current Liabilities).

Zimmer Biomet Holdings Change In Working Capital Historical Data

The historical data trend for Zimmer Biomet Holdings's Change In Working Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zimmer Biomet Holdings Change In Working Capital Chart

Zimmer Biomet Holdings Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Working Capital

Get a 7-Day Free Trial

-167.50

-429.80

-134.20

-311.40

-396.20

Zimmer Biomet Holdings Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Change In Working Capital	Get a 7-Day Free Trial															-108.60	-179.40	-133.30	-82.10	-1.40

Zimmer Biomet Holdings Change In Working Capital Calculation

Change In Working Capital for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-396 Mil.

Working Capital is a measure of a company's short term liquidity or its ability to cover short term liabilities. It is defined as the difference between a company's current assets and current liabilities.

Changes in Working Capital is reported in the cash flow statement since it is one of the major ways in which net income can differ from operating cash flow. It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement.

Use Wal-Mart Stores Inc (Jan 2014, Annual Data) as an example: Source: Wal-Mart Stores Inc 2014-01-31 10-K from SEC

Consolidated Statements of Cash Flows	Fiscal Years Ended	January 31,	(Amounts in millions)
Cash flows from operating activities:	2014	2013	2012
Changes in certain assets and liabilities, net of effects of acquisitions:
Receivables, net	(566)	(614)	(796)
Inventories	(1,667)	(2,759)	(3,727)
Accounts payable	531	1,061	2,687
Accrued liabilities	103	271	(935)
Accrued income taxes	(1,224)	981	994

For 2014-01-31, add all the items under 2014 collum together, Change in Working Capital was (566) + (1,667) + 531 + 103 + (1,224) = $ (2,823) Mil.

Zimmer Biomet Holdings Change In Working Capital Related Terms

Thank you for viewing the detailed overview of Zimmer Biomet Holdings's Change In Working Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Zimmer Biomet Holdings (Zimmer Biomet Holdings) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Zimmer Biomet Holdings Inc (NYSE:ZBH) » Definitions » Change In Working Capital

Comparable Companies

Traded in Other Exchanges

ZIM:Germany ZBH:Austria

Address

345 East Main Street, Warsaw, IN, USA, 46580

Website

https://www.zimmerbiomet.com

Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly two thirds of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, sports medicine, and related surgical products. The firm spun out its dental and spine businesses in 2022.

Executives

Syed A. Jafry	director	345 E. MAIN STREET, WARSAW IN 46580
Sreelakshmi Kolli	director	C/O ALIGN TECHNOLOGY INC., 2820 ORCHARD PARKWAY, SAN JOSE CA 94131
Christopher B Begley	director
Robert Hagemann	director	3 GIRALDA FARMS, MADISON NJ 07940
Michael W Michelson	director	2800 SAND HILL ROAD, SUITE 200, MENLO PARK CA 94025
Betsy J Bernard	director	711 HIGH STREET, DES MOINES IA 50392-0300
Arthur J Higgins	director	C/O ZIMMER, INC., P.O. BOX 708, WARSAW IN 46580
Chad F Phipps	officer: Assoc. Gen. Counsel, Corp. Sec	C/O ZIMMER, INC., P.O. BOX 708, WARSAW IN 46580
Zuilen Wilfred Van	officer: Pres, Europe, M. East & Africa	345 E. MAIN STREET, WARSAW IN 46580
Paul A Stellato	officer: VP, Controller & CAO	C/O XYLEM INC, 1 INTERNATIONAL DRIVE, RYE BROOK NY 10573
Sang Yi	officer: President, Asia Pacific	345 E. MAIN STREET, WARSAW IN 46580
Lori Winkler	officer: SVP and CHRO	345 E. MAIN STREET, WARSAW IN 46580
Rachel Ellingson	officer: SVP & CSO	345 E MAIN STREET, WARSAW K7 46580
Bryan C Hanson	director, officer: President and CEO	ZIMMER BIOMET HOLDINGS, 345 E. MAIN STREET, WARSAW IN 46580
Aure Bruneau	officer: Group President	345 E. MAIN STREET, WARSAW IN 46580